Madison Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madison Nguyen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abigail E. Overacre-Delgoffe
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
27 shared publications - Ansen B.P. Burr
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
27 shared publications - Bingxian Xie
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
27 shared publications - Dhivyaa Rajasundaram
Department of Pediatrics, University of Pittsburgh, PA, United States
27 shared publications - Diwakar Davar
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania
27 shared publications - Drew E. Hurd
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
27 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
The gut microbiota is necessary and sufficient to drive immunotherapy resistance due to sucralose. A, Mice consumed sucralose (0.09 mg/mL) in the drinking water for 14 days prior to antibiotic treatment and for the duration of the experiment. After 21 days of sucralose supplementation with or without antibiotics, mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with anti–PD-1 on days 9, 12, and 15. B, Tumor growth curve and overall survival plot of experiment described in A. CR, complete response. C, FMT experimental overview. Donor mice (red) were given sucralose-supplemented drinking water (0.09 mg/mL) for 2 weeks prior to donating stool. Stool was transferred to sucralose-naïve recipient mice (light pink) that had received broad-spectrum antibiotics for 7 days prior to transfer. Tumors were injected as previously described in 4A and measured until endpoint. D, Tumor growth curve of the experiment described in C. Data are a composite of three (B and C) independent experiments with five mice per group per experiment. Error bars represent the mean ± SEM. Two-way ANOVA (B and D) was used. *, P < 0.05.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
The gut microbiota is necessary and sufficient to drive immunotherapy resistance due to sucralose. A, Mice consumed sucralose (0.09 mg/mL) in the drinking water for 14 days prior to antibiotic treatment and for the duration of the experiment. After 21 days of sucralose supplementation with or without antibiotics, mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with anti–PD-1 on days 9, 12, and 15. B, Tumor growth curve and overall survival plot of experiment described in A. CR, complete response. C, FMT experimental overview. Donor mice (red) were given sucralose-supplemented drinking water (0.09 mg/mL) for 2 weeks prior to donating stool. Stool was transferred to sucralose-naïve recipient mice (light pink) that had received broad-spectrum antibiotics for 7 days prior to transfer. Tumors were injected as previously described in 4A and measured until endpoint. D, Tumor growth curve of the experiment described in C. Data are a composite of three (B and C) independent experiments with five mice per group per experiment. Error bars represent the mean ± SEM. Two-way ANOVA (B and D) was used. *, P < 0.05.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Responder-derived FMT is sufficient to restore immunotherapeutic response. A, Individual tumor growth curves from Fig. 4D with FMT. B and C, C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. Tumor area was measured every 3 days until endpoint. Four groups all received an FMT from an anti–PD-1 responder mouse donor. The following four groups were used: antibiotic treatment pre-FMT, continued sucralose consumption (hot pink), antibiotic treatment pre-FMT, stopped sucralose consumption (light pink), no antibiotics, continued sucralose consumption (purple), no antibiotics, stopped sucralose consumption (light blue). Individual tumor growth curves (B) and a composite growth curve and OS (C) are shown. Data are a composite of three (A) or two (B and C) independent experiments with five mice per group per replicate. Error bars represent the mean ± SEM. For growth curve statistics, two-way ANOVA was used. OS statistics were calculated using a log-rank Mantel–Cox test. *, P < 0.05. abx, antibiotics; CR, complete response.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Responder-derived FMT is sufficient to restore immunotherapeutic response. A, Individual tumor growth curves from Fig. 4D with FMT. B and C, C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. Tumor area was measured every 3 days until endpoint. Four groups all received an FMT from an anti–PD-1 responder mouse donor. The following four groups were used: antibiotic treatment pre-FMT, continued sucralose consumption (hot pink), antibiotic treatment pre-FMT, stopped sucralose consumption (light pink), no antibiotics, continued sucralose consumption (purple), no antibiotics, stopped sucralose consumption (light blue). Individual tumor growth curves (B) and a composite growth curve and OS (C) are shown. Data are a composite of three (A) or two (B and C) independent experiments with five mice per group per replicate. Error bars represent the mean ± SEM. For growth curve statistics, two-way ANOVA was used. OS statistics were calculated using a log-rank Mantel–Cox test. *, P < 0.05. abx, antibiotics; CR, complete response.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Appendix 1 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Appendix 1 shows the IRB approval for HCC 20-019.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessAppendix 1 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Appendix 1 shows the IRB approval for HCC 20-019.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S11 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S11 shows a volcano plot and pathway enrichment of T cells cultured in sucralose during activation and expansion.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S11 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S11 shows a volcano plot and pathway enrichment of T cells cultured in sucralose during activation and expansion.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Tables S1-4 show univariate and multivariate analysis of patient data.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Tables S1-4 show univariate and multivariate analysis of patient data.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S9 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S9 shows T cell proliferation and metabolism following sucralose culture during activation, expansion, or the entirety of culture.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S9 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S9 shows T cell proliferation and metabolism following sucralose culture during activation, expansion, or the entirety of culture.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S3 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S3 shows overall response rate and progression free response rate for patients consuming aspartame or saccharin.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S3 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S3 shows overall response rate and progression free response rate for patients consuming aspartame or saccharin.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Sucralose ablates immunotherapeutic responses. C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. Tumor area was measured every 3 days until endpoint. A, Experimental schematic. B, Tumor growth curves of mice consuming sucrose or sucralose in the drinking water during treatment with anti–PD-1. CR, complete response. C, Tumor growth curves in MC38 subcutaneous (circles) or B16 intradermal (squares) treated with anti–PD-1. Mice were sourced from either The Jackson Laboratory (Jax, open circles) or Taconic Biosciences (Taconic, closed circles). Mice were removed from study either when tumors reached 2 cm in either direction or if there was unresolved ulceration. Mean tumor growth lines halt once all mice in a treatment group were removed. D and E, C57BL/6 mice from either Taconic (D) or Jackson (E) consumed sucralose in their drinking water as in (C). They were subjected to the AOM-DSS protocol (injected with 10 mg/kg AOM on day 0 and given 3% DSS in the drinking water on days 7–14 and 28–35). Overall tumor number and composition of “large” tumors (>2 mm in any direction) are shown. Data are a composite of three (C) or two (B and D) independent experiments with five mice per group per experiment. Error bars represent the mean ± SEM. A two-way ANOVA (C) or Student t test (D) was used. *, P < 0.05; ns, not significant.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Sucralose ablates immunotherapeutic responses. C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. Tumor area was measured every 3 days until endpoint. A, Experimental schematic. B, Tumor growth curves of mice consuming sucrose or sucralose in the drinking water during treatment with anti–PD-1. CR, complete response. C, Tumor growth curves in MC38 subcutaneous (circles) or B16 intradermal (squares) treated with anti–PD-1. Mice were sourced from either The Jackson Laboratory (Jax, open circles) or Taconic Biosciences (Taconic, closed circles). Mice were removed from study either when tumors reached 2 cm in either direction or if there was unresolved ulceration. Mean tumor growth lines halt once all mice in a treatment group were removed. D and E, C57BL/6 mice from either Taconic (D) or Jackson (E) consumed sucralose in their drinking water as in (C). They were subjected to the AOM-DSS protocol (injected with 10 mg/kg AOM on day 0 and given 3% DSS in the drinking water on days 7–14 and 28–35). Overall tumor number and composition of “large” tumors (>2 mm in any direction) are shown. Data are a composite of three (C) or two (B and D) independent experiments with five mice per group per experiment. Error bars represent the mean ± SEM. A two-way ANOVA (C) or Student t test (D) was used. *, P < 0.05; ns, not significant.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S4 shows the individual tumor growth curves from mice consuming artificial sweeteners, overall survival, and tumor area. It also shows tumor growth curves for mice that were cohoused.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Supplementary Fig S4 shows the individual tumor growth curves from mice consuming artificial sweeteners, overall survival, and tumor area. It also shows tumor growth curves for mice that were cohoused.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Sucralose consumption shifts gut microbiome diversity and function. C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. A, Principal coordinate analysis (PCoA) plot of the gut microbiome of sucralose-consuming vs. -abstaining mice on day 38. Serial stool collections were obtained on days 0, 14, 28, and 38 after the start of sucralose consumption and sent for shallow shotgun sequencing. B, Cladogram with significantly overexpressed taxa in anti–PD-1 or sucralose + anti–PD-1 groups at day 38. In the cladogram, the size of the circle (node) encodes the –log10(FDR) value. C, Taxonomic relative abundance bar plots for the groups at day 38. Percent abundance on the y-axis indicates the mean abundance for all mice within each group. Asterisks label bacterial species that are arginine degrading and enriched in sucralose-consuming groups. D, Functional pathway analysis of sucralose + anti–PD-1 vs. anti–PD-1. Bar chart shows significant pathways with the default MaAsLin2 fdr threshold of <0.25. The MaAsLin2 coef value is reported on the x-axis. E, Functional pathway analysis of the arginine degradation pathway between sucralose + anti–PD-1 and anti–PD-1. Heatmap shows fold change of arginine-degrading enzymes expressed by bacteria in sucralose-consuming groups. Data are representative of one independent experiment with five mice per group. FDR, false discovery rate.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Sucralose consumption shifts gut microbiome diversity and function. C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. A, Principal coordinate analysis (PCoA) plot of the gut microbiome of sucralose-consuming vs. -abstaining mice on day 38. Serial stool collections were obtained on days 0, 14, 28, and 38 after the start of sucralose consumption and sent for shallow shotgun sequencing. B, Cladogram with significantly overexpressed taxa in anti–PD-1 or sucralose + anti–PD-1 groups at day 38. In the cladogram, the size of the circle (node) encodes the –log10(FDR) value. C, Taxonomic relative abundance bar plots for the groups at day 38. Percent abundance on the y-axis indicates the mean abundance for all mice within each group. Asterisks label bacterial species that are arginine degrading and enriched in sucralose-consuming groups. D, Functional pathway analysis of sucralose + anti–PD-1 vs. anti–PD-1. Bar chart shows significant pathways with the default MaAsLin2 fdr threshold of <0.25. The MaAsLin2 coef value is reported on the x-axis. E, Functional pathway analysis of the arginine degradation pathway between sucralose + anti–PD-1 and anti–PD-1. Heatmap shows fold change of arginine-degrading enzymes expressed by bacteria in sucralose-consuming groups. Data are representative of one independent experiment with five mice per group. FDR, false discovery rate.